anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

226,441-226,500 of 319,975

filter-aware
13
Includes study design details for a multicenter, randomized, double-blind, placebo-controlled trial.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
16
The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
20
Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
21
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
22
Includes footnotes regarding anti-dilution provisions and reverse stock split/warrant conversion context.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
23
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
24
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Golden Circle1 hit
25
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
01
Slide 1
Features a 3D rendering of a synapse.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
02
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
03
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
08
Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
Includes details on screen failures and co-treatment with Riluzole.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
Uses numbered icons for primary/secondary and a lightbulb icon for exploratory.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
Includes a footnote citation for the methodology definitions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
18
The slide uses icons to represent functional domains and provides specific clinical examples of what a 1-point change means for patient quality of life.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses a case study to validate the business model of combination therapies.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
25
The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
26
The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
27
The slide uses a grid layout to display five key advisors with their respective credentials and logos of their affiliated institutions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
28
The slide uses a grid layout to present institutional and corporate partners.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
29
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
30
Slide 30 of the deck.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
31
The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
32
The chart shows a divergence in SVC decline between the treatment and placebo groups over time.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
33
Data includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various motor and respiratory domains.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
02
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
03
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · ProblemLoop · Aha Moment1 hit
04
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · ProblemLoop · Aha Moment1 hit
05
The table compares NYCB's performance at two different dates (9/30/22 and 12/31/23) against a peer median as of 9/30/23.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
06
The slide uses a three-row layout to categorize key financial metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
Includes non-GAAP reconciliations note and rounding note.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
Includes non-GAAP adjustments and profitability metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
Includes footnotes explaining specific line items and non-GAAP metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
10
New York Community Bancorp | Results Presentation Deck | 42 slidesNew York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
11
The slide uses two pie charts to illustrate deposit diversification and risk profile.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
The chart illustrates the bridge between two balance sheet dates.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The chart highlights Flagstar's positive growth (+6.79%) against negative trends in the broader US banking sector.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
14
The table compares NYCB (as of Dec 31, 2023) against industry benchmarks (as of Sept 30, 2023).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit